Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.

MLA

Carvajal, René, et al. “Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.” JAMA Network Open, vol. 7, no. 4, Apr. 2024, p. e246345. EBSCOhost, https://doi.org/10.1001/jamanetworkopen.2024.6345.

APA

Carvajal, R., Zabalza, A., Carbonell-Mirabent, P., Martínez-Gómez, X., Esperalba, J., Pappolla, A., Rando, A., Cobo-Calvo, A., Tur, C., Rodriguez, M., Río, J., Comabella, M., Castilló, J., Rodrigo-Pendás, J. Á., Braga, N., Mongay-Ochoa, N., Guío-Sánchez, C., Vidal-Jordana, Á., Arrambide, G., & Rodríguez-Acevedo, B. (2024). Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab. JAMA Network Open, 7(4), e246345. https://doi.org/10.1001/jamanetworkopen.2024.6345

Chicago

Carvajal, René, Ana Zabalza, Pere Carbonell-Mirabent, Xavier Martínez-Gómez, Juliana Esperalba, Agustín Pappolla, Ariadna Rando, et al. 2024. “Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.” JAMA Network Open 7 (4): e246345. doi:10.1001/jamanetworkopen.2024.6345.